Anaphylactoid Reactions during Lipidapheresis in a Patient on ACE Inhibitor Therapy

2015 ◽  
pp. 234-236 ◽  
Author(s):  
Andreas Schwarzbeck
Keyword(s):  
Ace Inhibitor ◽  
Inhibitor Therapy ◽  
Anaphylactoid Reactions

Duration of cough following cessation of ACE inhibitor therapy

1995 ◽  
Vol 8 (1) ◽  
pp. 98-98 ◽  
Author(s):  
G LIP ◽  
J ZARIFIS ◽  
M BEEVERS ◽  
D BEEVERS
Keyword(s):  
Ace Inhibitor ◽  
Inhibitor Therapy

Angiotensin-Converting Enzyme Gene Polymorphism and Erythropoietin Requirement

2003 ◽  
Vol 23 (2) ◽  
pp. 111-115 ◽  
Author(s):  
Mira Varagunam ◽  
Daniel J. McCloskey ◽  
Paul J. Sinnott ◽  
Martin J. Raftery ◽  
Muhammed M. Yaqoob
Keyword(s):  
Renal Failure ◽  
Parathyroid Hormone ◽  
Angiotensin Converting Enzyme ◽  
Ace Inhibitor ◽  
Inhibitor Therapy ◽  
Converting Enzyme ◽  
C Reactive Protein ◽  
Dose Requirement ◽  
Reactive Protein ◽  
Significant Difference

Objectives To study the effect of angiotensin-converting enzyme (ACE) polymorphisms II, ID, and DD on erythropoietin (EPO) requirement in patients on continuous ambulatory peritoneal dialysis (CAPD) therapy. Design Retrospective observational study. Setting CAPD Unit, Royal London/St. Bartholomews Hospital, London, UK. Patients 46 patients on the transplant waiting list (age 20 – 70 years), on CAPD therapy for an average of 28 months, seen consecutively over a period of 3 months in the outpatients department. Main Outcome Measures Primary end point: EPO dose requirement in different ACE genotypes. Secondary end points: C-reactive protein, ferritin, parathyroid hormone, Kt/V, duration of dialysis, folate, cause of renal failure, and whether or not patients were on ACE inhibitor therapy. Results There was a statistically significant difference ( p < 0.05) in EPO requirement in the II/ID group compared to the DD group. The mean ± standard error of EPO for the II/ID group was 144 ± 15 U/kg/week, and for the DD group, 87 ± 9 U/kg/ week. The difference in EPO requirement could not be explained by age, C-reactive protein, ferritin, parathyroid hormone, Kt/V, duration of dialysis, folate, cause of renal failure, or whether or not patients were on ACE inhibitor therapy. Conclusion In CAPD patients, ACE genotype has predictive value when determining the EPO dosage, as the II/ID genotype may be associated with a suboptimal response.

scholarly journals Angiotensin-Converting Enzyme Insertion/Deletion Polymorphism and Severe Hypoglycemia Complicating Type 2 Diabetes: The Fremantle Diabetes Study

Endocrinology ◽  
2011 ◽  
Vol 152 (3) ◽  
pp. 1195-1195
Author(s):  
Wendy A. Davis ◽  
Simon G. A. Brown ◽  
Ian G. Jacobs ◽  
Max Bulsara ◽  
John Beilby ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Confidence Interval ◽  
Angiotensin Converting Enzyme ◽  
Ace Inhibitor ◽  
Severe Hypoglycemia ◽  
Community Dwelling ◽  
Inhibitor Therapy ◽  
First Episode ◽  
Converting Enzyme

Abstract Aims/Hypotheses: The aims of this study were to determine whether the angiotensin-converting enzyme (ACE) gene I/D polymorphisms independently predict severe hypoglycemia in community-dwelling type 2 patients. Methods: Six hundred two patients who were ACE genotyped at baseline and assessed in 1998 were followed up to the end of June 2006. Severe hypoglycemia was defined as that requiring documented health service use as the primary diagnosis. Cox proportional hazards modeling was used to determine the predictors of first episode and zero-inflated negative binomial regression modeling identified predictors of frequency. Results: Forty-nine patients (8.1%) experienced 63 episodes of severe hypoglycemia. After adjusting for previously identified significant independent predictors of time to first episode, both ACE DD genotype and ACE inhibitor therapy, but not their interaction, added to the model [hazard ratio (95% confidence interval): 2.34 (1.29–4.26), P = 0.006, and 1.77 (0.99–3.13), P = 0.052, respectively]. Similarly, after adjusting for previously identified risk factors for multiple episodes of severe hypoglycemia, ACE DD genotype was independently associated with increased risk [incidence relative risk (95% confidence interval): 1.80 (1.00–3.24), P = 0.050]. Conclusions/Interpretation: ACE DD genotype is associated with an increased the risk of the first episode of severe hypoglycemia and its subsequent frequency approximately 2-fold in well-characterized patients with type 2 diabetes. Consistent with previous case-control studies, ACE inhibitor therapy was a weak predictor of severe hypoglycemia. ACE I/D genotyping might provide useful adjunctive prognostic information when intensive glycemic control measures are contemplated.

Evaluation of ACE Inhibitor Therapy for Congestive Heart Failure in an Outpatient Setting

1998 ◽  
Vol 14 (1) ◽  
pp. 7-11 ◽  
Author(s):  
Barry E Bleske ◽  
Laura A Cornish ◽  
Steven R Erickson ◽  
John M Nicklas
Keyword(s):  
Heart Failure ◽  
Congestive Heart Failure ◽  
Ace Inhibitor ◽  
Standard Of Care ◽  
Outpatient Setting ◽  
Inhibitor Therapy ◽  
University Teaching ◽  
Patient Specific ◽  
Heart Failure Clinic ◽  
History Of

Objective: Angiotensin-converting enzyme (ACE) inhibitor therapy is considered the standard of care for the treatment of congestive heart failure. Despite this, clinical experience suggests that not all patients may be receiving ACE inhibitor therapy or may be receiving low dosages. This study was performed to better understand the use of ACE inhibitor therapy in clinical practice. Design and Participants: We reviewed the medical therapy of 110 patients with a history of congestive heart failure referred to an outpatient heart failure clinic at a university teaching hospital. Outcome Measures: This observational study evaluated the use of ACE inhibitors, including dosage, as well as other drugs to treat congestive heart failure. Results: Approximately 85% (93/110) of patients were receiving an ACE inhibitor. Twenty percent (22/110) were receiving enalapril 20 mg/d or more, captopril 150 mg/d or more, lisinopril 20 mg/d or more, or quinapril 40 mg/d or more. The remaining patients (n = 71) were receiving these drugs at lower dosages. However, 21 of the remaining patients (19% of all patients) were receiving lower dosages based on patient-specific parameters; 47 of the remaining patients (43% of all patients) were eligible to have their dosage increased. Ten eligible patients were not receiving an ACE inhibitor. The majority of patients were also receiving digoxin (70%) and loop diuretic (80%) therapy. Conclusions: Approximately 85% of patients were receiving ACE inhibitor therapy, with 9% of eligible patients not receiving an ACE inhibitor. In the patients receiving ACE inhibitor therapy, approximately 50% (47/93) were receiving dosages below those suggested in the guidelines. Overall, the use of ACE inhibitor therapy is varied and intervention appears required to ensure that all patients receive appropriate therapy for the treatment of congestive heart failure.

Sign in / Sign up

Export Citation Format

Share Document